GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Common Stock

Benevolent AI (Benevolent AI) Common Stock : $0.13 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Common Stock?

Benevolent AI's quarterly common stock increased from Dec. 2022 ($0.12 Mil) to Jun. 2023 ($0.13 Mil) and increased from Jun. 2023 ($0.13 Mil) to Dec. 2023 ($0.13 Mil).

Benevolent AI's annual common stock declined from Dec. 2021 ($0.32 Mil) to Dec. 2022 ($0.12 Mil) but then increased from Dec. 2022 ($0.12 Mil) to Dec. 2023 ($0.13 Mil).

Benevolent AI Common Stock Historical Data

The historical data trend for Benevolent AI's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Common Stock Chart

Benevolent AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial 0.28 0.32 0.32 0.12 0.13

Benevolent AI Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only 0.32 0.12 0.12 0.13 0.13

Benevolent AI Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Benevolent AI (Benevolent AI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Common Stock
Comparable Companies
Traded in Other Exchanges
BAI:Netherlands 2XA:Germany
Address
4-8 Maple Street, London, GBR, W1T 5HD
Website
https://www.benevolent.com
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.